Abstract
Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor (FcRn) thereby rescuing it from degradation. The first therapeutic Fc-fusion protein was introduced for the treatment of AIDS. The molecular designing is the first stage in production of Fc-fusion proteins. The amino acid residues in the Fc region and linked protein are very important in the bioactivity and affinity of the fusion proteins. Although, therapeutic monoclonal antibodies are the top selling biologics but the application of therapeutic Fc-fusion proteins in clinic is in progress and among these medications Etanercept is the most effective in therapy. At present, eleven Fc-fusion proteins have been approved by FDA. There are novel Fc-fusion proteins which are in pre-clinical and clinical development. In this article, we review the molecular and biological characteristics of Fc-fusion proteins and then further discuss the features of novel therapeutic Fc-fusion proteins.
Keywords: Fc-fusion proteins, immunotherapy, FcRn, antibody, Fc region.
Current Medicinal Chemistry
Title:Fc-fusion Proteins in Therapy: An Updated View
Volume: 24 Issue: 12
Author(s): Reza Jafari, Naime M. Zolbanin, Houshang Rafatpanah, Jafar Majidi and Tohid Kazemi*
Affiliation:
- Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, P.O. Box: 5165683146, Tabriz,Iran
Keywords: Fc-fusion proteins, immunotherapy, FcRn, antibody, Fc region.
Abstract: Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor (FcRn) thereby rescuing it from degradation. The first therapeutic Fc-fusion protein was introduced for the treatment of AIDS. The molecular designing is the first stage in production of Fc-fusion proteins. The amino acid residues in the Fc region and linked protein are very important in the bioactivity and affinity of the fusion proteins. Although, therapeutic monoclonal antibodies are the top selling biologics but the application of therapeutic Fc-fusion proteins in clinic is in progress and among these medications Etanercept is the most effective in therapy. At present, eleven Fc-fusion proteins have been approved by FDA. There are novel Fc-fusion proteins which are in pre-clinical and clinical development. In this article, we review the molecular and biological characteristics of Fc-fusion proteins and then further discuss the features of novel therapeutic Fc-fusion proteins.
Export Options
About this article
Cite this article as:
Jafari Reza, Zolbanin M. Naime, Rafatpanah Houshang, Majidi Jafar and Kazemi Tohid*, Fc-fusion Proteins in Therapy: An Updated View, Current Medicinal Chemistry 2017; 24 (12) . https://dx.doi.org/10.2174/0929867324666170113112759
DOI https://dx.doi.org/10.2174/0929867324666170113112759 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mucoadhesive Formulation Designs for Oral Controlled Drug Release at the Colon
Current Pharmaceutical Design Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature
Current Drug Safety Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Polymer Membrane and Cell Models for Drug Discovery
Combinatorial Chemistry & High Throughput Screening The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Photothermal Ablation of Cancer Cells Using Folate-Coated Gold/ Graphene Oxide Composite
Current Drug Delivery Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer
Current Drug Targets Inhibition of Carbonic Anhydrase IX: A New Strategy Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Towards Characterization of the Human Urinary Peptidome
Combinatorial Chemistry & High Throughput Screening Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design ETS Proteins and MMPs: Partners in Invasion and Metastasis
Medicinal Chemistry Reviews - Online (Discontinued) Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry